| Care and Maintenance of Vision |
1 |
1 |
| Retinal Diseases |
0 |
0.95 |
| Vascular Endothelial Growth Factor |
0 |
0.58 |
| Healthcare and Medical Technology |
0 |
0.55 |
| Orbit |
0 |
0.52 |
| Biologic Therapy |
0 |
0.46 |
| Retina |
0 |
0.45 |
| Eye Infection |
0 |
0.41 |
| Diabetic Microvascular Complications |
0 |
0.23 |
| Biomedical Technology |
0 |
0.19 |
| Clinical Research |
0 |
0.19 |
| Drug Delivery System |
0 |
0.19 |
| Visual Acuity |
0 |
0.19 |
| Exudative ARMD |
0 |
0.16 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.16 |
| Corticosteroids |
0 |
0.13 |
| Diabetic Retinopathy |
0 |
0.13 |
| Diabetic Macular Edema |
0 |
0.11 |
| Antibiotics |
0 |
0.09 |
| Anxiety Disorder |
0 |
0.09 |
| B-Cell Lymphoma |
0 |
0.09 |
| Cornea and External Disease |
0 |
0.09 |
| Genomic Medicine |
0 |
0.09 |
| Glaucoma |
0 |
0.09 |
| Macular Edema |
0 |
0.09 |
| Tyrosine Kinase Inhibitor |
0 |
0.09 |
| Washington DC |
0 |
0.09 |
| Anatomy |
0 |
0.07 |
| Anxiety |
0 |
0.07 |
| Edema |
0 |
0.07 |
| Fibroblast Growth Factor |
0 |
0.07 |
| Food and Drug Administration (FDA) |
0 |
0.07 |
| Hand |
0 |
0.07 |
| Illinois |
0 |
0.07 |
| Lymphoma |
0 |
0.07 |
| Macular Degeneration |
0 |
0.07 |
| Pharmacokinetics |
0 |
0.07 |
| Retinopathy |
0 |
0.07 |
| Small Molecule Inhibitor |
0 |
0.07 |
| Topical Medication |
0 |
0.07 |
| Tyrosine Kinase |
0 |
0.07 |
| Washington |
0 |
0.07 |